CD155 inhibitor B7 is a blood-brain barrier-permeable small molecule CD155 (Poliovirus receptor, PVR) inhibitor, shows potent anti-proliferative activity GBM cell line LN229 with IC50 of 3.43 uM.
B7 shows an IC50 ranging from 3.43 to 14.60 uM for four human GBM cell lines (U87-MG, U251-MG, LN229, and U118-MG) using MTS assay.
(10 and 20 mg/kg) significantly inhibited tumor growth in U-87 xenograft model.
B7 significantly inhibited the proliferation of GSCs with IC50 of 6.1 uM, inhibiting proliferation, inducing apoptosis, and blocking sphere formation.
B7 enhances the cytotoxicity of NK-92 cells by targeting CD155-mediated immune checkpoint interactions.
demonstrates significant anti-GBM effects with dual-mode anti-GSC mechanisms that directly suppressed GSCs while concurrently activated NK cell-mediated immunity via the CD155/TIGIT/CD226 immune checkpoint axis within the tumor immune microenvironment (TIME).
B7 weakens the binding affinity of CD155-TIGIT and strengthens the binding of CD155-CD226 in protein interaction assays.